Harmony Biosciences Holdings, Inc. Common Stock
HRMYHarmony Biosciences Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with neurological and psychiatric disorders. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company specializes in treatments for rare and unmet medical conditions, with a notable focus on narcolepsy and other sleep-related disorders.
Company News
Bridge City Capital fully exited its position in Harmony Biosciences Holdings, selling all 237,103 shares worth approximately $7.77 million during Q1 2026. The stake, which represented 2.6% of the fund's AUM in the prior quarter, was completely liquidated. Harmony Biosciences, a rare neurological disorder treatment developer, has underperformed t...
The Russell 2000 small-cap index has outperformed major indices, rising 8.40% in the past month. With Q1 2026 earnings season underway, analysts expect small-cap earnings growth of 18.4% compared to 9.8% for S&P 500 companies. The article highlights three undervalued small-cap stocks with significant upside potential: Goosehead Insurance (technol...
Harmony Biosciences' CFO Sandip Kapadia sold all 20,961 of her directly held shares for approximately $752,800 on January 15, 2026, fully exiting her equity position. The sale was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider exit, the company reported strong Q3 2025 earnings and expects to generate over $1 billion in revenu...
Harmony Biosciences has achieved remarkable financial success with its narcolepsy drug Wakix, growing sales at 40% CAGR to nearly $870 million and achieving profitability with $186 million in net income. However, the stock has remained flat since its IPO due to concerns including a 2023 short-seller report alleging fraud, pending patent expiratio...
The Developmental and Epileptic Encephalopathies (DEE) market is expected to grow significantly due to approved medications like EPIDIOLEX, rising demand for novel treatments, and the introduction of potential emerging therapies. However, the discontinuation of emerging therapies may impede this growth.
